The Busiest Dealmakers Of 2022

2022 Deal-Making Led By Sanofi, J&J And Roche

With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.    

Busy
• Source: Shutterstock

As 2022 draws to a close, an unusually low number of marquee deals have been made in the biopharma sector. But it has been a hectic year nonetheless, with a high volume of deal-making and the lower valuations reflecting broader economic factors and continuing trends seen in recent years toward smaller, easier-to-manage deals.

Macroeconomic concerns stemming from inflation and rising interest rates, supply-chain uncertainty earlier in the year and the continuing war in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Outlook Archive

More from Outlook